Autonomic Nervous System Drugs Practice Questions

Q: Which skeletal muscle relaxant is preferred in patients with liver and renal disease?

Atracurium. **Explanation:** The correct answer is **Atracurium** (Option A). **Why Atracurium is preferred:** Atracurium is unique because it does not rely on the liver or kidneys for its elimination. It undergoes **Hofmann elimination**, a spontaneous non-enzymatic degradation in the plasma at physiological pH and temperature. Additionally, it is metabolized by **ester hydrolysis** via non-specific plasma esterases. This makes it the drug of choice for patients with multi-organ failure, particularly renal or hepatic impairment, as its duration of action remains unchanged. **Analysis of Incorrect Options:** * **B. Mivacurium:** While it is metabolized by plasma cholinesterase (like succinylcholine), its duration can be significantly prolonged in patients with liver disease due to decreased synthesis of cholinesterase enzymes. * **C. Gallamine:** This is a long-acting relaxant that is **excreted unchanged entirely by the kidneys**. It is strictly contraindicated in renal failure as it leads to profound cumulative toxicity. * **D. Vecuronium:** This drug is primarily metabolized by the liver and excreted in bile. Its action is significantly prolonged in patients with cirrhosis or hepatic cholestasis. **NEET-PG High-Yield Pearls:** * **Cisatracurium:** An isomer of atracurium, it also undergoes Hofmann elimination but is more potent and produces less **laudanosine** (a metabolite of atracurium that can cause seizures at high levels). It is often preferred over atracurium in ICU settings. * **Rocunorium:** The non-depolarizing blocker with the fastest onset of action, making it an alternative for rapid sequence intubation if succinylcholine is contraindicated. * **Sugammadex:** A specific reversal agent used for the rapid termination of neuromuscular blockade induced by Vecuronium and Rocuronium.

Q: Laudanosine is a metabolite of which neuromuscular blocking agent?

Atracurium. **Explanation:** **Atracurium** is the correct answer because it undergoes a unique spontaneous degradation process known as **Hofmann elimination** (a non-enzymatic, pH and temperature-dependent pathway) and ester hydrolysis. The primary metabolic byproduct of these processes is **Laudanosine**, a tertiary amine. * **Why Atracurium is correct:** Laudanosine is the major metabolite of both Atracurium and its isomer, Cisatracurium. However, Atracurium produces significantly higher levels of Laudanosine (approximately 3–5 times more) compared to Cisatracurium. * **Why other options are incorrect:** * **Cisatracurium:** While it also produces Laudanosine, Atracurium is the classic association in exams due to the higher volume produced. In a single-choice question, Atracurium is the primary answer. * **Pancuronium:** This is a long-acting aminosteroid NMBA primarily excreted unchanged by the kidneys (80%). It does not produce Laudanosine. * **Gallamine:** This is an older, long-acting agent excreted entirely unchanged by the kidneys. It is now largely obsolete in clinical practice. **Clinical Pearls for NEET-PG:** 1. **CNS Toxicity:** Laudanosine is a **CNS stimulant**. In high concentrations (rare in routine clinical use but possible in prolonged ICU infusions), it can cross the blood-brain barrier and potentially cause **seizures**. 2. **Organ Independence:** Because Atracurium relies on Hofmann elimination, it is the drug of choice (along with Cisatracurium) for patients with **renal or hepatic failure**. 3. **Histamine Release:** Unlike Cisatracurium, Atracurium is associated with dose-dependent histamine release, which can cause flushing, hypotension, and bronchospasm.

Q: Which one of the following is a contraindication to the use of ergot derivatives?

Obstructive vascular disease. ### Explanation **Correct Option: C. Obstructive vascular disease** Ergot derivatives (such as Ergotamine and Ergonovine) act as **partial agonists at alpha-adrenergic and 5-HT receptors** [4]. Their primary hemodynamic effect is **potent, prolonged vasoconstriction** [3]. In patients with obstructive vascular diseases—such as Coronary Artery Disease (CAD), Raynaud’s phenomenon, or Buerger’s disease—this vasoconstriction can critically reduce blood flow, leading to myocardial infarction, gangrene, or severe tissue ischemia [2]. Therefore, any pre-existing compromise in vascular patency is a strict contraindication [2]. **Why the other options are incorrect:** * **A. Migraine:** Ergotamine and Dihydroergotamine (DHE) are established treatments for acute migraine attacks [1]. They work by constricting dilated cerebral vessels and inhibiting neurogenic inflammation. * **B. Hyperprolactinemia:** Bromocriptine and Cabergoline are ergot derivatives that act as **D2 receptor agonists** [4]. They inhibit prolactin release from the anterior pituitary and are the first-line treatment for prolactinomas. * **C. Postpartum hemorrhage (PPH):** Ergometrine (Ergonovine) is used to prevent and treat PPH [1]. It induces forceful, rhythmic contractions of the uterine smooth muscle (oxytocic effect), which compresses bleeding vessels at the placental site [4]. **High-Yield Clinical Pearls for NEET-PG:** * **Ergotism (St. Anthony’s Fire):** Chronic poisoning characterized by intense burning pain and dry gangrene due to persistent vasoconstriction [3]. * **Drug Interaction:** Ergot derivatives should not be used within 24 hours of **Triptans** due to the risk of additive vasospasm. * **Specific Contraindications:** Pregnancy (due to fetal distress/abortion), uncontrolled hypertension, and sepsis [2]. * **Bromocriptine** is also used in Parkinson’s disease and Type 2 Diabetes (as a quick-release formulation) [4].

Q: Which drug is not used in the management of glaucoma?

Atropine. **Explanation** The correct answer is **Atropine** because it is a potent **muscarinic antagonist (mydriatic-cycloplegic)**. In the eye, Atropine causes mydriasis (dilation of the pupil) by paralyzing the sphincter pupillae muscle. This leads to the crowding of the iris tissue into the iridocorneal angle, which can obstruct the drainage of aqueous humor through the trabecular meshwork. Consequently, Atropine can precipitate or worsen **acute angle-closure glaucoma** and is strictly contraindicated in such patients. **Analysis of Incorrect Options:** * **Timolol:** A non-selective **beta-blocker** and the first-line treatment for open-angle glaucoma. It works by decreasing the production of aqueous humor from the ciliary body. * **Pilocarpine:** A **miotic (direct cholinergic agonist)**. It causes contraction of the sphincter pupillae and ciliary muscle, which pulls the iris away from the angle and opens the trabecular meshwork, facilitating aqueous drainage. * **Physostigmine:** An **anticholinesterase (indirect cholinergic agonist)**. Like pilocarpine, it induces miosis and improves aqueous outflow; though less commonly used today than prostaglandins or beta-blockers, it remains a valid pharmacological option for glaucoma. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC)** for Acute Angle-Closure Glaucoma: **Acetazolamide** (IV) and **Mannitol** (to rapidly lower IOP), followed by Pilocarpine. * **DOC** for Chronic Open-Angle Glaucoma: **Latanoprost** (PGF2α analog). * **Apraclonidine** is used to prevent IOP spikes after laser trabeculoplasty. * **Atropine Flush:** A side effect of systemic atropine toxicity, characterized by dry, red skin and hyperthermia.

Q: Drug H is most like which of the following agents?

Epinephrine. ***Epinephrine*** - Drug H demonstrates activity at **all adrenergic receptor subtypes** (α1, α2, β1, β2), which perfectly matches **epinephrine's broad receptor profile**. - Epinephrine is a **non-selective adrenergic agonist** that activates both **alpha and beta receptors** with equal potency, producing diverse physiological effects. *Isoproterenol* - Acts as a **selective β-adrenergic agonist** (β1 and β2) with **no alpha receptor activity**. - Would not match Drug H's profile since it lacks **α1 and α2 receptor stimulation**. *Norepinephrine* - Primarily activates **α1, α2, and β1 receptors** but has **minimal β2 activity**. - Differs from Drug H because it shows **weak or absent β2 receptor stimulation**. *Phenylephrine* - Functions as a **selective α1-adrenergic agonist** with **no beta receptor activity**. - Cannot match Drug H's profile due to complete absence of **β1 and β2 receptor stimulation**.

Q: Botulinum toxin affects all of the following except:

Central Nervous System. **Explanation:** Botulinum toxin, produced by *Clostridium botulinum*, acts by cleaving **SNARE proteins** (specifically Synaptobrevin, SNAP-25, and Syntaxin). This prevents the fusion of synaptic vesicles with the presynaptic membrane, thereby inhibiting the release of **Acetylcholine (ACh)** at all cholinergic nerve terminals. **Why the Central Nervous System (CNS) is the correct answer:** Botulinum toxin is a large protein molecule that **cannot cross the blood-brain barrier (BBB)**. Therefore, when administered systemically or locally, it does not affect the CNS. Its effects are strictly limited to the peripheral nervous system. **Analysis of Incorrect Options:** * **Neuromuscular Junction (NMJ):** This is the primary site of action. By blocking ACh release at the NMJ, the toxin causes flaccid paralysis (the hallmark of botulism). * **Preganglionic Junctions:** All preganglionic fibers (both sympathetic and parasympathetic) are cholinergic. The toxin effectively blocks transmission at these autonomic ganglia. * **Post-ganglionic Nerves:** All parasympathetic post-ganglionic nerves and sympathetic post-ganglionic nerves supplying sweat glands are cholinergic. These are susceptible to the toxin, leading to autonomic symptoms like dry mouth and anhidrosis. **NEET-PG High-Yield Pearls:** * **Mechanism:** Proteolysis of SNARE proteins (Irreversible inhibition). * **Clinical Uses:** Strabismus, blepharospasm, achalasia cardia, spasticity, and cosmetic reduction of wrinkles. * **Antidote:** Toxin effects are permanent at the specific nerve terminal; recovery requires the sprouting of new nerve terminals (axonal regrowth). * **Contrast:** Unlike Botulinum (which blocks release), **Tetanus toxin** undergoes retrograde axonal transport to the CNS, where it inhibits GABA/Glycine release, causing spastic paralysis.

Q: Which drug is used to treat dry mouth (xerostomia) in patients undergoing cancer chemotherapy?

Cevimeline. **Explanation:** **Cevimeline** is the preferred drug for treating xerostomia (dry mouth) associated with Sjögren’s syndrome or radiation/chemotherapy-induced salivary gland dysfunction. It is a **selective M3 muscarinic agonist**. Since M3 receptors are primarily responsible for stimulating salivary and lacrimal secretions, Cevimeline effectively increases saliva production. Compared to other cholinergic drugs, it has a longer duration of action and a better side-effect profile due to its relative selectivity. **Analysis of Incorrect Options:** * **Oxotremorine (A):** This is a potent muscarinic agonist but is primarily used as a research tool to induce parkinsonian-like tremors in animal models. It has no clinical application in treating xerostomia. * **Methacholine (B):** This is a non-selective muscarinic agonist. Its clinical use is restricted to the **Methacholine Challenge Test** for diagnosing bronchial hyperreactivity (Asthma). It is not used for xerostomia due to its significant cardiovascular and pulmonary side effects. * **Pilocarpine (D):** While Pilocarpine *is* used to treat xerostomia, it is a non-selective muscarinic agonist (M1, M2, M3). It has a shorter half-life than Cevimeline and more frequent side effects (sweating, flushing, and urinary urgency). In many clinical scenarios, Cevimeline is favored for its M3 selectivity. **NEET-PG High-Yield Pearls:** * **M3 Receptors:** Located on exocrine glands (sweat, salivary, lacrimal) and smooth muscles (bronchi, bladder, gut). * **Drug of Choice:** Cevimeline is often cited as the drug of choice for Sjögren’s syndrome-related dry mouth. * **Contraindications:** Muscarinic agonists should be avoided in patients with uncontrolled asthma, COPD, or acute iritis. * **Pilocarpine** remains the drug of choice for **Acute Angle Closure Glaucoma** (miotic agent).

Q: Which of the following is a beta-blocker with a beta-2 receptor agonist action?

Celiprolol. **Explanation:** The correct answer is **Celiprolol**. **1. Why Celiprolol is correct:** Celiprolol is a unique, third-generation beta-blocker. Its pharmacological profile is characterized by **selective $\beta_1$ antagonism** (cardioselective) combined with **partial $\beta_2$ receptor agonism** (Intrinsic Sympathomimetic Activity - ISA) [1]. This $\beta_2$ agonist action leads to peripheral vasodilation and bronchodilation, which helps counteract the typical side effects of beta-blockers, such as cold extremities or bronchospasm. It also possesses weak $\alpha_2$ blocking and nitric oxide-modulating properties. **2. Analysis of Incorrect Options:** * **A. Labetalol:** This is a non-selective $\beta$ blocker with additional **$\alpha_1$ blocking** activity. It does not have $\beta_2$ agonist action. It is a drug of choice in pregnancy-induced hypertension. * **B. Carvedilol:** This is a non-selective $\beta$ blocker with **$\alpha_1$ blocking** and potent antioxidant properties. It is widely used in chronic heart failure but lacks $\beta_2$ agonism. * **C. Tilisolol:** This is a non-selective beta-blocker used primarily in Japan. It is unique because it has **potassium channel opening** properties (vasodilation), but it does not act as a $\beta_2$ agonist [1]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Vasodilatory Beta-blockers:** Remember them by the mechanism [1]: * **$\alpha_1$ blockade:** Labetalol, Carvedilol. * **$\beta_2$ agonism:** Celiprolol, Carteolol. * **NO (Nitric Oxide) release:** Nebivolol (most cardioselective), Nipradilol. * **$K^+$ channel opening:** Tilisolol. * **Celiprolol** is particularly useful in hypertensive patients with asthma or peripheral vascular disease due to its $\beta_2$ agonist-mediated bronchodilation and vasodilation.

Question 1

Which skeletal muscle relaxant is preferred in patients with liver and renal disease?

Accepted Answer

Atracurium

Answer

Mivacurium

Answer

Gallamine

Answer

Vecuronium

Question 2

Laudanosine is a metabolite of which neuromuscular blocking agent?

Accepted Answer

Atracurium

Answer

Cisatracurium

Answer

Pancuronium

Answer

Gallamine

Question 3

Which one of the following is a contraindication to the use of ergot derivatives?

Accepted Answer

Obstructive vascular disease

Answer

Migraine

Answer

Hyperprolactinemia

Answer

Postpartum hemorrhage

Question 4

A diabetic patient with autonomic neuropathy presents with dizziness and hypotension upon waking. What is the drug of choice for this condition?

Accepted Answer

Midodrine

Answer

Dopamine / Dobutamine

Answer

Isoproterenol

Answer

Clonidine

Question 5

Which drug is not used in the management of glaucoma?

Accepted Answer

Atropine

Answer

Timolol

Answer

Physostigmine

Answer

Pilocarpine

Question 6

Drug H is most like which of the following agents?

Accepted Answer

Epinephrine

Answer

Isoproterenol

Answer

Norepinephrine

Answer

Phenylephrine

Question 7

Botulinum toxin affects all of the following except:

Accepted Answer

Central Nervous System

Answer

Neuromuscular junction

Answer

Preganglionic junction

Answer

Post-ganglionic nerves

Question 8

Which of the following provides the best explanation for neostigmine being preferred over physostigmine for treating Myasthenia gravis?

Accepted Answer

Neostigmine has an additional direct agonistic action on the nicotinic receptor in the muscle end plate.

Answer

Neostigmine is better absorbed orally.

Answer

Neostigmine has a longer duration of action.

Answer

Neostigmine penetrates the blood-brain barrier.

Question 9

Which drug is used to treat dry mouth (xerostomia) in patients undergoing cancer chemotherapy?

Accepted Answer

Cevimeline

Answer

Oxotremorine

Answer

Methacholine

Answer

Pilocarpine

Question 10

Which of the following is a beta-blocker with a beta-2 receptor agonist action?

Accepted Answer

Celiprolol

Answer

Labetalol

Answer

Carvedilol

Answer

Tilisolol

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?